PT-141 (Bremelanotide) Seasonal Use Considerations

What Bremelanotide Does and Why Season Matters

Bremelanotide is a cyclic heptapeptide melanocortin-receptor agonist approved by the FDA in August 2019 under the trade name Vyleesi for premenopausal women with acquired, generalized HSDD. [1] Its mechanism differs completely from phosphodiesterase-5 inhibitors: it does not act on vascular smooth muscle but instead activates MC3R and MC4R in hypothalamic and limbic circuits to amplify central sexual-desire signaling. [2]

That central mechanism is precisely why seasonal biology is clinically relevant. The melanocortin system does not operate in isolation. It interacts bidirectionally with the melatonin axis, the hypothalamic-pituitary-gonadal (HPG) axis, and serotonin pathways, all of which undergo measurable seasonal oscillation in response to photoperiod changes. [3] A patient who responds well to 1.75 mg in June may notice a blunted or altered response in December without any change in dosing technique or adherence.

Prescribers who ignore seasonality risk attributing pharmacological underperformance to patient factors, when the driver is a neurobiological mismatch between the drug's mechanism and the patient's current neuroendocrine environment.

The Melanocortin System in Brief

MC3R and MC4R are G-protein-coupled receptors expressed densely in the arcuate nucleus, paraventricular nucleus, and medial preoptic area. [4] Activation of MC4R in the medial preoptic area, in particular, has been shown in rodent models to increase female proceptive and receptive behaviors, a finding that maps onto the clinical observation of bremelanotide's desire-specific (rather than arousal-specific) effect in women. [4]

Alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous MC3R/MC4R ligand, is derived from pro-opiomelanocortin (POMC). POMC neurons in the arcuate nucleus are tonically regulated by estrogen, leptin, and light-entrained signals. [5] Seasonal shifts in any of these regulators can alter the receptor environment into which bremelanotide is delivered.

FDA Approval and the RECONNECT Evidence Base

The key RECONNECT program consisted of two randomized, double-blind, placebo-controlled phase 3 trials enrolling a combined N=1,247 premenopausal women with HSDD. [6] Across both trials, bremelanotide 1.75 mg subcutaneous produced statistically significant improvements in the Female Sexual Function Index desire domain and in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 distress score compared with placebo (P<0.001 for both co-primary endpoints). [6]

The absolute magnitude of benefit was modest: mean change in satisfying sexual events per month was approximately 0.5 events greater than placebo. Neither trial stratified outcomes by season or by baseline melatonin status, which means seasonal effects remain an area of clinical inference rather than direct trial evidence. That gap is exactly what this article addresses.

Winter and Low-Light Months: The Highest-Risk Seasonal Window

Winter presents the most consistent neurobiological challenge for bremelanotide users. Reduced daylight shortens the circadian photoperiod, which signals the pineal gland to extend nocturnal melatonin secretion. [7] In northern latitudes above 40 degrees, this extension can add 1.5 to 2.5 hours of elevated melatonin output per night compared with summer values. [7]

Melatonin and Melanocortin Cross-Talk

Melatonin receptors (MT1 and MT2) are expressed in the hypothalamic suprachiasmatic nucleus (SCN) and arcuate nucleus, overlapping substantially with MC3R/MC4R distribution. [8] Animal studies demonstrate that high melatonin tone suppresses POMC neuronal firing and reduces alpha-MSH release. [9] If this suppression also attenuates MC4R sensitivity, exogenous bremelanotide may have a smaller effective signal to work against an already-dampened endogenous background.

No published human pharmacokinetic study has directly measured whether melatonin co-elevation alters bremelanotide's receptor occupancy. However, the clinical implication is that winter patients who report diminished response should have photoperiod-adjusted sleep hygiene assessed before dose escalation is considered. Bright-light therapy (10,000 lux for 30 minutes each morning) has been shown in randomized trials to suppress daytime melatonin carryover and improve serotonergic tone in seasonal affective disorder (SAD). [10]

Seasonal Affective Disorder as a Complicating Comorbidity

SAD affects an estimated 1 to 6 percent of the US population and is substantially more prevalent in women, the primary HSDD population. [11] Serotonin dysregulation underlies both SAD and HSDD: decreased serotonin transporter availability in winter has been documented by PET imaging in SAD patients. [12] Because bremelanotide's nausea side effect (40.9% incidence in RECONNECT) [6] is mediated partly through serotonergic pathways in the area postrema, clinicians should anticipate that patients with winter-onset depressive symptoms may experience higher nausea rates and lower desire-specific benefit during low-light months.

Prescribers should screen for SAD using the Seasonal Pattern Assessment Questionnaire (SPAQ) at the autumn visit. A patient with a Global Seasonality Score above 11 warrants co-management with a psychiatrist or primary care provider before bremelanotide is continued through winter. The American Psychiatric Association's DSM-5 specifies that the seasonal pattern specifier requires at least two consecutive years of autumn/winter MDD episodes with full remission in spring. [13]

Practical Winter Dosing Guidance

Patients using bremelanotide in winter should be counseled to:

• Time the injection on evenings following a morning bright-light session, not on days of unbroken indoor darkness.
• Stay well-hydrated, as dry winter air increases insensible fluid loss and may exaggerate the transient blood-pressure dip seen post-dose.
• Report any new or worsening depressive symptoms promptly, since HSDD and SAD share an overlapping neurobiological substrate and both require active management.

The FDA label instructs patients to limit use to 8 doses per month. [1] There is no evidence supporting dose increases beyond 1.75 mg to compensate for winter blunting; the single-dose ceiling is defined by the blood-pressure and nausea safety profile, not by receptor saturation.

Spring and Autumn Transitions: Circadian Flux and Hormonal Reset

Equinox transitions, roughly March and September, represent periods of rapid photoperiod change. The SCN resets its phase relationship to the light-dark cycle over a span of days to weeks. During this recalibration, melatonin onset and offset shift noticeably, and gonadotropin-releasing hormone (GnRH) pulsatility can transiently fluctuate. [14]

LH and FSH Pulse Seasonality

A 1996 cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism found that LH pulse frequency in premenopausal women was highest in spring months (March through May), correlating with longer photoperiod. [15] Higher LH pulse frequency supports estradiol production. Estradiol, in turn, upregulates POMC gene expression in the arcuate nucleus. [5] The net effect is that the endogenous melanocortin tone supporting bremelanotide's mechanism of action may be modestly higher in spring than in any other season.

Clinically, this suggests that spring represents a favorable window for initiating bremelanotide in a new patient. The baseline neuroendocrine environment may be more permissive, allowing the prescriber to establish whether the drug is working before moving into the summer or winter neuroendocrine states.

Managing Autumn Onset of HSDD Symptoms

Many women with HSDD report that symptom severity worsens in autumn. A study of sexual activity patterns across 19,000 Twitter posts (a proxy behavioral dataset) found consistent seasonal troughs in expressed sexual content in autumn and winter compared with spring and summer. [16] While social-media data carry obvious methodological limitations, the direction aligns with the photoperiod-melatonin-HPG model described above.

For patients who recognize an autumn pattern to their HSDD, prescribers may consider starting or restarting bremelanotide in September, before the melatonin environment reaches its winter peak, to establish behavioral and psychological momentum around sexual activity. This is not a dose-timing adjustment; the drug is taken as-needed. The strategy is about patient preparation and expectation-setting rather than pharmacokinetic optimization.

Summer Considerations: Heat, Hydration, and the Blood-Pressure Effect

Bremelanotide produces a transient decrease in blood pressure, predominantly systolic, peaking within 12 minutes of injection and resolving within 12 hours. [1] The mean maximal decrease in the RECONNECT trials was approximately 6 mmHg systolic and 3 mmHg diastolic. [6] In summer, two additional variables can amplify this effect.

Heat-Related Vasodilation

High ambient temperatures trigger cutaneous vasodilation as a thermoregulatory response. Skin blood flow can increase from a resting 200 to 500 mL per minute to more than 7,000 mL per minute during vigorous heat stress. [17] While bremelanotide users are not exercising strenuously during drug action, even mild summer heat (ambient temperature above 30 degrees Celsius) increases baseline vasodilatory tone. Adding bremelanotide's central melanocortin-mediated blood-pressure effect on top of heat-related vasodilation may produce symptomatic hypotension in susceptible patients, particularly those on antihypertensive medications.

The FDA label contraindicates bremelanotide in patients with high uncontrolled cardiovascular disease risk and advises caution in anyone taking antihypertensive or sympatholytic agents. [1] In summer, patients on even low-dose antihypertensives should be explicitly reminded to measure standing blood pressure before injection on hot days.

Dehydration and Injection-Site Absorption

Subcutaneous absorption kinetics depend partly on local tissue perfusion. Moderate dehydration (body-water deficit of 2 percent) reduces skin turgor and subcutaneous perfusion, which could theoretically slow bremelanotide's absorption from the abdomen or thigh injection site, delaying the recommended 45-minute pre-activity dosing window. [18] Patients should be instructed to drink at least 500 mL of water in the 2 hours before summer-evening injections.

Summer nausea management also deserves brief mention. Heat itself is a nausea trigger through vagal afferent pathways. Combined with bremelanotide's 40.9% nausea incidence, [6] hot-weather use may increase the proportion of patients who need antiemetic rescue. Ginger extract (1 g oral, taken 30 minutes prior) was shown in a Cochrane-reviewed meta-analysis to reduce nausea NRS scores by a mean of 1.2 points vs. Placebo, which may offer a low-risk adjunct. [19]

Hormonal Cycling: A Year-Round Confound

HSDD in premenopausal women exists against a background of cyclical estradiol and progesterone variation. Estradiol peaks at mid-cycle (approximately 200 to 400 pg/mL), then drops sharply in the late luteal phase. Late-luteal and early-follicular estradiol troughs coincide with the period of lowest self-reported desire in most premenopausal women. [20]

The interaction between menstrual-cycle phase and bremelanotide response has not been formally studied in a phase 3 trial. Based on the POMC-estradiol interaction described above, [5] a reasonable clinical framework is:

• High probability of response: Mid-follicular to ovulatory phase (days 8 to 14 of a 28-day cycle), combined with a high-light season (April through August).
• Moderate probability of response: Mid-luteal phase (days 16 to 22), any season, assuming stable estradiol support.
• Lower probability of response: Late-luteal phase (days 23 to 28) combined with winter low-light months. Both variables reduce the central melanocortin tone that bremelanotide must work against.

This framework is an original HealthRX clinical synthesis based on published neuroendocrinology; it has not been prospectively validated in a randomized trial and should be used to guide expectation-setting conversations, not to restrict access to the drug.

Thyroid Function and Seasonal Metabolic Shifts

Thyroid-stimulating hormone (TSH) levels show a seasonal pattern in the general population, with TSH peaking in December and January and nadir in July, documented across multiple large epidemiological datasets. [21] Subclinical hypothyroidism, defined as TSH above 4.5 mIU/L with normal free T4, affects approximately 4 to 8 percent of women and is associated with reduced libido independent of HSDD diagnosis. [22]

A woman with borderline thyroid function in summer (TSH 3.0 mIU/L) may cross into subclinical hypothyroid territory in winter (TSH 5.2 mIU/L) without any change in thyroid pathology. That thyroid shift alone can reduce sexual desire scores enough to confound bremelanotide's apparent efficacy. Annual autumn TSH screening in HSDD patients on bremelanotide is a defensible clinical practice and consistent with American Thyroid Association screening recommendations for women over 35. [23]

Drug Interactions With Seasonal Relevance

Naltrexone and Opioid Receptor Considerations

Naltrexone, used off-label in low-dose formulations for immune modulation, is an opioid-receptor antagonist. The FDA label for bremelanotide warns that naltrexone co-administration may reduce bremelanotide's efficacy, because opioid-receptor pathways modulate melanocortin neurotransmission in the hypothalamus. [1] Patients who increase naltrexone doses in winter for SAD-adjacent mood support should be counseled that this may dampen bremelanotide response.

Serotonergic Agents and Winter Prescribing

Patients prescribed SSRIs or SNRIs for winter depression face two compounding challenges: SSRIs independently cause sexual dysfunction in 40 to 70 percent of users, [24] and the shared serotonergic mechanism with bremelanotide's nausea pathway means GI side effects may be additive. The prescriber should document whether an SSRI was added or dose-adjusted seasonally before attributing any decline in bremelanotide effect to the drug itself.

Flibanserin (Addyi), the alternative FDA-approved HSDD treatment, carries a contraindication with moderate-to-strong CYP3A4 inhibitors. [25] Bremelanotide does not share this interaction but is contraindicated with naltrexone, as noted. Seasonal medication additions should always be reviewed against both agents if a patient is transitioning between them.

Patient Communication: A Seasonal Check-In Framework

The RECONNECT program's 24-week treatment duration [6] spans approximately two seasons. Yet standard prescribing practice rarely includes structured seasonal reassessment. The American College of Obstetricians and Gynecologists (ACOG) recommends that HSDD treatment include regular reassessment of response and ongoing patient education about contributing psychosocial and physiological factors. [26]

A practical seasonal check-in framework for bremelanotide patients includes:

1. Autumn (September/October): Screen for SAD (SPAQ), check TSH, review antidepressant status, counsel on winter melatonin environment, confirm injection technique and storage (below 25 degrees Celsius, protected from light per FDA label).
2. Winter (December/January): Assess response at current dose, review blood-pressure readings, evaluate nausea frequency, confirm no new serotonergic or opioid-receptor medications added.
3. Spring (March/April): Assess whether improved photoperiod correlates with improved response; this is a good window to re-establish baseline FSDS-DAO scores.
4. Summer (June/July): Counsel on hydration before injection, review antihypertensive status, address heat-related nausea strategies.

This four-point annual review adds roughly 10 minutes per visit and aligns HSDD management with the kind of chronic-disease monitoring applied to conditions like hypothyroidism and mood disorders.

Monitoring Parameters Across the Year

Across all seasons, the following monitoring parameters apply to any patient on bremelanotide:

• Blood pressure before the first injection and after any new medication is added, per FDA label guidance. [1]
• Skin hyperpigmentation: bremelanotide can cause focal hyperpigmentation of the face, breasts, and gingiva with repeated dosing. This effect is melanocortin-receptor-mediated and is not expected to vary by season, but sun exposure in summer may make any pigmentation change more visible. The FDA label notes this risk. [1]
• Pregnancy test if menstrual irregularity occurs. Bremelanotide is classified FDA Pregnancy Category X equivalent (contraindicated); a positive pregnancy test requires immediate discontinuation. [1]
• FSDS-DAO Item 13 score at each follow-up to quantify distress response. A clinically meaningful response threshold of 1.0-point improvement on this validated scale was used as a supportive endpoint in RECONNECT. [6]